Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Boronic Acids
  • Lymphoma, Follicular
  • Protease Inhibitors
  • Pyrazines

abstract

  • Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.

publication date

  • December 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4035037

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2141.2009.07775.x

PubMed ID

  • 19624539

Additional Document Info

start page

  • 652

end page

  • 5

volume

  • 146

number

  • 6